Cargando…
Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
Introduction: Intrahepatic cholangiocarcinoma (ICC) has devastating outcomes owing to its advanced stage at diagnosis and high recurrence after hepatectomy. There is no preferred treatment for recurrent ICC. We retrospectively reviewed our patients who underwent repeated operations for recurrent ICC...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029635/ https://www.ncbi.nlm.nih.gov/pubmed/35455657 http://dx.doi.org/10.3390/jpm12040540 |
_version_ | 1784691928355307520 |
---|---|
author | Tsai, Chun-Yi Wang, Shang-Yu Chan, Kun-Ming Lee, Wei-Chen Chen, Tse-Ching Yeh, Ta-Sen Jan, Yi-Yin Yeh, Chun-Nan |
author_facet | Tsai, Chun-Yi Wang, Shang-Yu Chan, Kun-Ming Lee, Wei-Chen Chen, Tse-Ching Yeh, Ta-Sen Jan, Yi-Yin Yeh, Chun-Nan |
author_sort | Tsai, Chun-Yi |
collection | PubMed |
description | Introduction: Intrahepatic cholangiocarcinoma (ICC) has devastating outcomes owing to its advanced stage at diagnosis and high recurrence after hepatectomy. There is no preferred treatment for recurrent ICC. We retrospectively reviewed our patients who underwent repeated operations for recurrent ICCs based on their different indications to appraise the outcomes. Methods: In all, 160 out of 216 patients with ICC (71.4%) experienced recurrence after curative resection from 1977 to 2014. The patterns of recurrence were categorized according to the locations and numbers of recurrent tumors. Results: Patients with merely intrahepatic recurrence (n = 38) had superior overall survival (OS) compared with those with beyond intrahepatic recurrence (p < 0.0001). Twenty-seven out of 160 patients (16.8%) underwent repeat hepatectomy or/with metastatectomy for recurrence and had superior OS when compared to the remaining 133 patients who received nonoperative treatment/palliation (85.6 months versus 20.9 months, p < 0.001). Furthermore, patients suitable for repeat hepatectomy in the intrahepatic recurrent group (n = 12) had superior post-recurrence overall survival (PROS) than the remaining 26 patients receiving nonoperative treatment (61.6 months versus 14.7 months, p < 0.05). Conclusion: Liver is the most commonly involved site of recurrent ICC. However, merely intrahepatic recurrence may have a favorable prognosis compared to recurrence involving other sites. Aggressive hepatectomy may provide a survival benefit in selected patients. |
format | Online Article Text |
id | pubmed-9029635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90296352022-04-23 Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients Tsai, Chun-Yi Wang, Shang-Yu Chan, Kun-Ming Lee, Wei-Chen Chen, Tse-Ching Yeh, Ta-Sen Jan, Yi-Yin Yeh, Chun-Nan J Pers Med Article Introduction: Intrahepatic cholangiocarcinoma (ICC) has devastating outcomes owing to its advanced stage at diagnosis and high recurrence after hepatectomy. There is no preferred treatment for recurrent ICC. We retrospectively reviewed our patients who underwent repeated operations for recurrent ICCs based on their different indications to appraise the outcomes. Methods: In all, 160 out of 216 patients with ICC (71.4%) experienced recurrence after curative resection from 1977 to 2014. The patterns of recurrence were categorized according to the locations and numbers of recurrent tumors. Results: Patients with merely intrahepatic recurrence (n = 38) had superior overall survival (OS) compared with those with beyond intrahepatic recurrence (p < 0.0001). Twenty-seven out of 160 patients (16.8%) underwent repeat hepatectomy or/with metastatectomy for recurrence and had superior OS when compared to the remaining 133 patients who received nonoperative treatment/palliation (85.6 months versus 20.9 months, p < 0.001). Furthermore, patients suitable for repeat hepatectomy in the intrahepatic recurrent group (n = 12) had superior post-recurrence overall survival (PROS) than the remaining 26 patients receiving nonoperative treatment (61.6 months versus 14.7 months, p < 0.05). Conclusion: Liver is the most commonly involved site of recurrent ICC. However, merely intrahepatic recurrence may have a favorable prognosis compared to recurrence involving other sites. Aggressive hepatectomy may provide a survival benefit in selected patients. MDPI 2022-03-29 /pmc/articles/PMC9029635/ /pubmed/35455657 http://dx.doi.org/10.3390/jpm12040540 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tsai, Chun-Yi Wang, Shang-Yu Chan, Kun-Ming Lee, Wei-Chen Chen, Tse-Ching Yeh, Ta-Sen Jan, Yi-Yin Yeh, Chun-Nan Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients |
title | Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients |
title_full | Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients |
title_fullStr | Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients |
title_full_unstemmed | Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients |
title_short | Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients |
title_sort | hepatectomy or/with metastatectomy for recurrent intrahepatic cholangiocarcinoma: of promise for selected patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029635/ https://www.ncbi.nlm.nih.gov/pubmed/35455657 http://dx.doi.org/10.3390/jpm12040540 |
work_keys_str_mv | AT tsaichunyi hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients AT wangshangyu hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients AT chankunming hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients AT leeweichen hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients AT chentseching hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients AT yehtasen hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients AT janyiyin hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients AT yehchunnan hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients |